METADATE CD CII
Generic Name and Formulations:
Methylphenidate HCl 10mg, 20mg, 30mg, 40mg, 50mg, 60mg; ext-rel caps (contains immediate-release + ext-rel beads); contains sucrose.
Indications for METADATE CD:
Attention deficit hyperactivity disorder.
Adults and Children:
Take before breakfast. Swallow whole or sprinkle contents onto applesauce (swallow immediately); do not crush, chew, or divide beads. <6yrs: not established. ≥6yrs: initially 20mg once daily, may increase weekly by 10–20mg/day; max 60mg once daily.
During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family. Severe hypertension. Angina. Cardiac arrhythmias. Heart failure. Recent MI. Hyperthyroidism. Thyrotoxicosis. Surgery.
History of drug dependence or alcoholism; monitor for abnormal behavior. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR, CBCs, differential, platelet counts. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Avoid alcohol. Caution with pressor agents. May potentiate anticonvulsants (eg, phenobarbital, phenytoin, primidone), oral anticoagulants, tricyclics, SSRIs, phenylbutazone. May be affected by agents that alter urinary pH. Risk of serotonin syndrome with serotonergic drugs.
Headache, anorexia, abdominal pain, insomnia, dizziness, nervousness; priapism, hypertension, tachycardia, visual disturbances.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Ivacaftor Improves Insulin Secretion in Children With Cystic Fibrosis
- Genetic Testing Recommended for Familial Hypercholesterolemia
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry